BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11588846)

  • 1. Impact of screening on incidence and mortality of prostate cancer in the United States.
    Potosky AL; Feuer EJ; Levin DL
    Epidemiol Rev; 2001; 23(1):181-6. PubMed ID: 11588846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
    Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
    Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
    Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
    J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Welch HG; Albertsen PC
    J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database.
    Stephenson RA
    Urol Clin North Am; 2002 Feb; 29(1):173-81. PubMed ID: 12109343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of increasing detection in the rising incidence of prostate cancer.
    Potosky AL; Miller BA; Albertsen PC; Kramer BS
    JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 9. A population model of prostate cancer incidence.
    Tsodikov A; Szabo A; Wegelin J
    Stat Med; 2006 Aug; 25(16):2846-66. PubMed ID: 16397859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.
    Legler JM; Feuer EJ; Potosky AL; Merrill RM; Kramer BS
    Cancer Causes Control; 1998 Oct; 9(5):519-27. PubMed ID: 9934717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
    Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ
    Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of screening on prostate cancer rates and trends.
    Mettlin C
    Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying the role of PSA screening in the US prostate cancer mortality decline.
    Etzioni R; Tsodikov A; Mariotto A; Szabo A; Falcon S; Wegelin J; DiTommaso D; Karnofski K; Gulati R; Penson DF; Feuer E
    Cancer Causes Control; 2008 Mar; 19(2):175-81. PubMed ID: 18027095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.
    Hankey BF; Feuer EJ; Clegg LX; Hayes RB; Legler JM; Prorok PC; Ries LA; Merrill RM; Kaplan RS
    J Natl Cancer Inst; 1999 Jun; 91(12):1017-24. PubMed ID: 10379964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
    Houston KA; King J; Li J; Jemal A
    J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?
    Winter A; Sirri E; Jansen L; Wawroschek F; Kieschke J; Castro FA; Krilaviciute A; Holleczek B; Emrich K; Waldmann A; Brenner H;
    BJU Int; 2017 Apr; 119(4):550-559. PubMed ID: 27208546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.
    Brawley OW
    Cancer; 1997 Nov; 80(9):1857-63. PubMed ID: 9351560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
    Colli JL; Amling CL
    Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer incidence and mortality rates and trends in the United States and Canada.
    McDavid K; Lee J; Fulton JP; Tonita J; Thompson TD
    Public Health Rep; 2004; 119(2):174-86. PubMed ID: 15192905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.